Candidiasis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Injection, Ointment, Oral), By Drug Type (Polyene, Azole, Echinocandin, Other), By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis), By End-User (Hospitals and Clinics, Retail Pharmacies, Other), By Region and Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 3.51 Billion
CAGR (2026-2031)	6.29%
Fastest Growing Segment	Oral
Largest Market	North America
Market Size (2031)	USD 5.06 Billion

Market Overview

The Global Candidiasis Therapeutics Market is projected to grow from USD 3.51 Billion in 2025 to USD 5.06 Billion by 2031 at a 6.29% CAGR. Candidiasis therapeutics comprise pharmaceutical interventions formulated to treat infections caused by various Candida species, encompassing conditions from superficial mucocutaneous manifestations to severe systemic candidiasis. Key drivers supporting market growth include the increasing global prevalence of candidiasis, particularly among the expanding immunocompromised patient population, such as individuals with HIV/AIDS, cancer, or organ transplants. Furthermore, growing public awareness and advancements in diagnostic technologies, facilitating earlier and more accurate detection of these infections, significantly contribute to market expansion.

A significant challenge impeding market expansion is the escalating issue of antifungal resistance, exemplified by the increasing cases of multidrug-resistant strains like Candida auris, which complicates treatment regimens. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), in 2025, antimicrobial resistance, which encompasses fungal threats, accounted for approximately five million deaths worldwide, underscoring the urgent need for novel therapeutic solutions.

Key Market Drivers

Rising Incidence of Candidiasis
The rising global incidence of candidiasis significantly fuels the demand for effective therapeutic interventions. This widespread increase in fungal infections, encompassing various Candida species, strains healthcare systems and necessitates continuous advancements in treatment options. The escalating number of reported cases underscores the urgent need for new and improved antifungal drugs and diagnostics. For instance, according to the UK Health Security Agency, in May 2025, bloodstream infections caused by yeast in England rose by 4% in 2024 compared with 2023, increasing from 2,170 to 2,247 reports. This trend highlights the persistent challenge posed by these infections and their direct impact on public health worldwide.

Expanding Immunocompromised Patient Population
Concurrently, the expanding immunocompromised patient population represents another critical driver for the Global Candidiasis Therapeutics Market. Individuals with weakened immune systems, such as organ transplant recipients, cancer patients undergoing chemotherapy, and those with HIV/AIDS, are at a substantially higher risk of developing severe and invasive candidiasis. These vulnerable patient groups require specialized and potent antifungal treatments to manage or prevent life-threatening infections. According to the Global Observatory on Donation and Transplantation (GODT), in March 2026, a record 173,727 solid organ transplants were performed worldwide in 2024, representing a 2% global increase compared with 2023. This growing demographic necessitates ongoing research and development into novel candidiasis therapies to address their complex medical needs. Furthermore, according to Wellcome Leap, in May 2026, a $50 million funding round was announced to support the development of technologies aimed at reducing antimicrobial resistance, including antifungal agents.

Download Free Sample Report

Key Market Challenges

The escalating issue of antifungal resistance presents a formidable challenge to the global candidiasis therapeutics market. The emergence and widespread prevalence of multidrug-resistant strains, particularly Candida auris, significantly complicate treatment regimens, diminishing the effectiveness of existing pharmaceutical interventions. This resistance leads to prolonged hospital stays, increased healthcare expenditures, and higher rates of treatment failure, directly impacting patient outcomes and the economic viability of current therapeutic options.

This challenge is further exacerbated by a constrained pipeline for novel antifungal agents. According to the World Health Organization, in its April 2025 report, only nine antifungal medicines were in clinical development against priority fungal pathogens, with merely three of these candidates in Phase 3 trials. This limited developmental activity forecasts few new drug approvals within the coming decade, creating a substantial void in the market for effective treatments against evolving resistant candidiasis strains. The reduced availability of innovative therapies directly hampers market expansion by restricting growth opportunities and delaying the introduction of solutions capable of addressing the unmet medical need posed by resistant infections.

Key Market Trends

The global candidiasis therapeutics market is significantly shaped by the accelerated development of novel antifungal agents, representing a crucial response to the evolving challenge of drug resistance. This trend highlights intensified research and development efforts aimed at introducing new therapeutic options with improved efficacy and broader spectrum activity against various Candida species. These advancements are vital for expanding the arsenal of treatments beyond existing classes, which face increasing resistance concerns. For instance, the University of Exeter's FAILSAFE project has directed over £2.8 million in one year to support 135 researchers worldwide in developing new antifungal drugs and formulations. This focused investment underscores a broader industry and academic drive to overcome current treatment limitations.

Concurrently, strategic collaborations are increasingly driving antifungal innovation, fostering partnerships between pharmaceutical companies and biotechnology firms to accelerate the discovery and progression of next-generation therapies. These alliances leverage diverse expertise and resources, pooling intellectual capital and financial backing to tackle complex drug development challenges. Such collaborations often involve significant milestone payments and royalties, incentivizing targeted research and development efforts. As an illustration, according to a news article in Fierce Biotech, in January 2026, Basilea Pharmaceutica entered a collaboration with Prokaryotics to develop a broad-spectrum antifungal, with Prokaryotics potentially receiving up to $48.5 million in milestone payments. This approach facilitates a more rapid translation of scientific discoveries into viable clinical candidates, addressing the urgent unmet medical need within the candidiasis therapeutics market.

Segmental Insights

The oral route of administration segment is emerging as the fastest growing in the Global Candidiasis Therapeutics Market, largely due to its inherent patient convenience and widespread accessibility. Oral formulations facilitate easier self-administration at home, significantly improving patient adherence to treatment regimens. This mode of delivery also offers broad clinical utility, effectively managing a range of candidiasis infections from superficial to systemic forms. Furthermore, the cost-effectiveness of oral antifungal drugs and the prevalent availability of various azole-based medications contribute significantly to its rapid expansion and market dominance.

Regional Insights

North America dominates the Global Candidiasis Therapeutics Market due to its advanced healthcare infrastructure and high public awareness of candidiasis infections. The region benefits from significant healthcare expenditure and favorable reimbursement policies, which facilitate access to a broad range of innovative antifungal therapies. Additionally, a strong presence of key pharmaceutical companies and robust research and development activities drive the introduction of novel treatments. The stringent regulatory environment ensures the availability of effective and safe therapeutic options, solidifying North America's leading position in the global market.

Recent Developments

• In April 2026, ISHA Therapeutics received Qualified Infectious Disease Product (QIDP) designation from the U.S. FDA for ISHA-004, its innovative antifungal candidate for treating oropharyngeal candidiasis. This designation, granted by the FDA's Division of Infectious Diseases, supports the development of therapies for serious or life-threatening infections, including those caused by drug-resistant pathogens. ISHA-004 is a novel oral thin-film formulation of a potent antifungal agent, designed to adhere to oropharyngeal mucosal surfaces for targeted drug delivery at the infection site. The company plans to advance this program into clinical development later in 2026.
• In January 2026, Basilea Pharmaceutica Ltd and Prokaryotics Inc. announced a collaboration to jointly develop a novel, first-in-class broad-spectrum antifungal. This partnership targets severe invasive infections, including those caused by various Candida strains, Aspergillus, and rare molds. The agreement leverages Prokaryotics' expertise in discovering new anti-infectives and Basilea's capabilities in advancing drugs to market. The joint efforts are focused on antifungal molecules with a distinct mechanism of action, addressing the critical need for new treatments against drug-resistant fungal pathogens.
• In August 2025, CorMedix Inc. entered into a definitive agreement to acquire Melinta Therapeutics, LLC, a commercial-stage company with a portfolio of innovative therapies. This acquisition included Melinta's approved antifungal, REZZAYO® (rezafungin for injection), which is indicated for the treatment of candidemia and invasive candidiasis in adults. REZZAYO is a novel once-weekly echinocandin, and its addition to CorMedix's offerings aimed to position the company as a leader in the specialty pharmaceutical sector. A Phase III study for REZZAYO in the prophylaxis of invasive fungal infections was ongoing at the time.
• In February 2025, Texas A&M College of Dentistry, in collaboration with Shear Kershman Laboratories and Innovative MedTech Inc., announced an agreement to study BioViscid. BioViscid is a pharmaceutical delivery mechanism designed for antifungal medication to more effectively treat oral candidiasis, commonly known as oral thrush, and enhance patient adherence. This partnership combines academic research excellence with healthcare expertise and technological prowess to develop advanced technologies. Early efforts will concentrate on cancer patients, with future plans to invite broader patient participation in the studies.

Key Market Players

• Basilea Pharmaceutica Ltd
• Astellas Pharma Inc.
• SCYNEXIS, Inc.
• NovaDigm Therapeutics
• Mycovia Pharmaceuticals, Inc.
• Cidara Therapeutics Inc.
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Novabiotics Limited

By Route of Administration	By Drug Type	By Anatomy Type	By End-User	By Region
Injection Ointment Oral	Polyene Azole Echinocandin Other	Oral Candidiasis Vulvovaginal Candidiasis Cutaneous Candidiasis Invasive Candidiasis Systemic Candidiasis	Hospitals and Clinics Retail Pharmacies Other	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Candidiasis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Candidiasis Therapeutics Market, By Route of Administration:

• Injection
• Ointment
• Oral

• Candidiasis Therapeutics Market, By Drug Type:

• Polyene
• Azole
• Echinocandin
• Other

• Candidiasis Therapeutics Market, By Anatomy Type:

• Oral Candidiasis
• Vulvovaginal Candidiasis
• Cutaneous Candidiasis
• Invasive Candidiasis
• Systemic Candidiasis

• Candidiasis Therapeutics Market, By End-User:

• Hospitals and Clinics
• Retail Pharmacies
• Other

• Candidiasis Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE